Tempest Therapeutics Inc
TPST
Company Profile
Business description
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
Contact
2000 Sierra Point Parkway
Suite 400
BrisbaneCA94005
USAT: +1 415 798-8589
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
17
Stocks News & Analysis
stocks
Are investors missing the boat on this future ASX leader?
The market is underestimating the clear path to profitability.
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
stocks
Ask the analyst: Why have markets shunned APA Group?
Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,456.80 | 15.00 | -0.18% |
| CAC 40 | 7,440.60 | 16.93 | 0.23% |
| DAX 40 | 20,377.37 | 106.04 | 0.52% |
| Dow JONES (US) | 42,518.28 | 221.16 | 0.52% |
| FTSE 100 | 8,262.86 | 61.32 | 0.75% |
| HKSE | 19,286.07 | 66.29 | 0.34% |
| NASDAQ | 19,044.39 | 43.71 | -0.23% |
| Nikkei 225 | 38,444.58 | 29.72 | -0.08% |
| NZX 50 Index | 12,943.57 | 59.19 | 0.46% |
| S&P 500 | 5,842.91 | 6.69 | 0.11% |
| S&P/ASX 200 | 8,213.30 | 17.70 | -0.22% |
| SSE Composite Index | 3,227.12 | 13.82 | -0.43% |